Moreover, the genetically engineered T cells ectopically expressing two allogeneic HLA-C*08:02-restricted TCRs targeting KRAS G12D neoantigens were injected into the patient with metastatic PC and regressed the visceral metastases of the patient (37). This evidence concerns the gene KRAS and pachyonychia congenita.